Serum vitamin D levels may be a potentially modifiable factor associated with survival in follicular lymphoma (FL), according to an analysis of two cohort studies of patients with previously untreated FL.
Using baseline serum samples of 25-hydroxyvitamin D, investigators analyzed the adjusted progression-free survival (PFS) hazard ratio (HR) and overall survival HR for patients in SWOG and Lymphoma Study Association (LYSA) trials. In patients who were vitamin D deficient (<20 ng/mL in SWOG or <10 ng/mL in LYSA), the following PFS and overall survival HRs were as follows:
Citation: Kelly JL, Salles G, Goldman B, et al. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol. 2015. pii: JCO.2014.57.5092.
This Week's Must Reads
Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.
Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.
Adjuvant doxorubicin and ifosfamide boost outcomes in soft tissue sarcomas, Pasquali S et al. ASCO 2018, Abstract 115118.
Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030
Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005
Must Reads in Lymphoma & Plasma Cell Disorders
Private Insurance Linked to Better Outcomes in Follicular Lymphoma, Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035.
PET/CT provides MCL staging information, Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.
Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505
Revised International Pediatric Non-Hodgkin Lymphoma Staging System, Expert panel publishes evidence-based system
Link Between Vitamin D and Lymphoma Survival, Analysis of patients in SWOG and LYSA trials